LIVECAST Markets Briefs Calendar

Research

News Search AI Market Assistant Charts & News Instrument directory Macro Politics News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar News Search AI Market Assistant Charts & News Instrument directory Macro Politics News Archive Account

Home News ArchiveECB Cuts Commerzbank’s 2027 Pillar 2 Requirement to 2.10%

Live News REGULATION FLASH M impact Oct 27, 2026, 01:28 PM UTC

ECB Cuts Commerzbank’s 2027 Pillar 2 Requirement to 2.10%

SquawkNews Desk

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

No ticker tags on this item.

Related stories

US Appeals Court Affirms Validity of Venezuela’s PDVSA 2020 Bonds A US appeals court affirmed the validity of Venezuela’s PDVSA 2020 bonds. M impact | REGULATION | Oct 27, 2026, 03:48 PM UTC Brazil Treasury and Central Bank Seek Rationality, May Buy Back Bonds Today Finance Minister Durigan said the Treasury and Central Bank are seeking rationality, with a possible bond buyback today. L impact | REGULATION | Oct 27, 2026, 03:43 PM UTC Alibaba Obtains Injunction Against Pentagon Restrictions Alibaba obtained an injunction against Pentagon restrictions tied to an alleged link to the Chinese military. M impact | REGULATION | Oct 27, 2026, 03:43 PM UTC Brazil Central Bank Estimates 242 Lenders Missed Minimum Capital Requirements Brazil’s central bank estimates that 242 financial institutions did not meet minimum capital requirements. M impact | REGULATION | Oct 27, 2026, 03:43 PM UTC UK NICE Recommends NHS Funding for Arrowhead’s Redemplo in Adults With FCS The UK National Institute for Health and Care Excellence recommends NHS funding for Redemplo (plozasiran) for adults with genetically confirmed familial chylomicronemia syndrome. M impact | REGULATION | Oct 27, 2026, 03:37 PM UTC MHRA Grants Marketing Authorisation for Redemplo in Adults With FCS Arrowhead Pharmaceuticals says the MHRA granted marketing authorisation for Redemplo (plozasiran) to treat familial chylomicronemia syndrome in adults. M impact | REGULATION | Oct 27, 2026, 03:37 PM UTC

SQUAWK/NEWS

Independent financial newsroom. Editorial expertise and proprietary AI. Paid LiveCast brings live headlines, chart context and priority audio to your trading day. Free research tools remain available.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

News & Research

Open LiveCast
Session Briefs
Macro
Politics
News Archive

Markets & Tools

Charts & News
Markets Overview
US Stocks
Market Movers
Economic Calendar
Policy Calendar
AI Market Assistant
News Search
Instrument Directory

Guides

Charts & News Guide
How LiveCast Works
What Is an Audio Squawk?
Why News Moves Markets
News for Traders
How to Trade the News

Plans & API

Plans & Pricing
Institutional API
RSS Feed

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

© 2026 SquawkNews

Privacy Policy Terms of Use

SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.